Literature DB >> 10600457

Expression of a recombinant Toxoplasma gondii ROP2 fragment as a fusion protein in bacteria circumvents insolubility and proteolytic degradation.

A Jacquet1, V Daminet, M Haumont, L Garcia, S Chaudoir, A Bollen, R Biemans.   

Abstract

A 268-amino-acid-residue carboxy-terminal antigenic fragment of the Toxoplasma gondii rhoptry protein ROP2 (recROP2(t), residues 196-464) was expressed in Escherichia coli. This recombinant fragment was produced at low concentration and in a highly insoluble form. By contrast, the level of recROP2(t) production was drastically greater when the same coding sequence was fused to the C-terminus of thioredoxin (TRX) or to the maltose-binding protein (MBP) gene. While both fusion proteins were found to be mainly insoluble, solubilization could be achieved without significant degradation. MBP was more efficient than TRX in increasing the recovery of soluble protein with more than 10% of total MBP-recROP2(t) being readily expressed in a soluble form. Moreover, the insoluble form of MBP-recROP2(t) could be correctly refolded with a recovery of more than 80%. Both forms of MBP-recROP2(t) were purified to homogeneity by amylose chromatography. In contrast, the refolding of TRX-recROP2(t) promoted aggregation of the protein, which was prevented by the use of zwitterionic detergent during the one-step purification by gel filtration. Subsequent proteolytic cleavages of purified TRX-recROP2(t) and of MBP-recROP2(t) led respectively to the complete degradation or to the truncation of the recROP2(t) moiety. However, recROP2(t), despite the presence of the fusion partners, adopted a suitable conformation recognized by human serum-derived antibodies from T. gondii-seropositive individuals. Finally, both fusion proteins were able to induce specific humoral and cell-mediated immune response to the ROP2 fragment. Such fusions could represent an alternative to study the immunogenicity of T. gondii proteins which are difficult to produce because of insolubility and degradation. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10600457     DOI: 10.1006/prep.1999.1150

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  11 in total

1.  High level of expression of the Toxoplasma gondii-recombinant Rop2 protein in Escherichia coli as a soluble form for optimal use in diagnosis.

Authors:  M Nigro; V Martin; F Kaufer; L Carral; S O Angel; V Pszenny
Journal:  Mol Biotechnol       Date:  2001-07       Impact factor: 2.695

2.  Novel protein purification system utilizing an N-terminal fusion protein and a caspase-3 cleavable linker.

Authors:  Brett Feeney; Erik J Soderblom; Michael B Goshe; A Clay Clark
Journal:  Protein Expr Purif       Date:  2005-10-27       Impact factor: 1.650

Review 3.  Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies.

Authors:  Sudhir Sahdev; Sunil K Khattar; Kulvinder Singh Saini
Journal:  Mol Cell Biochem       Date:  2007-09-12       Impact factor: 3.396

4.  Protein interaction module-assisted function X (PIMAX) approach to producing challenging proteins including hyperphosphorylated tau and active CDK5/p25 kinase complex.

Authors:  Dexin Sui; Xinjing Xu; Xuemei Ye; Mengyu Liu; Maxwell Mianecki; Chotirat Rattanasinchai; Christopher Buehl; Xiexiong Deng; Min-Hao Kuo
Journal:  Mol Cell Proteomics       Date:  2014-11-10       Impact factor: 5.911

5.  Molecular cloning, overproduction, purification and biochemical characterization of the p39 nsp2 protease domains encoded by three alphaviruses.

Authors:  Di Zhang; József Tözsér; David S Waugh
Journal:  Protein Expr Purif       Date:  2008-10-30       Impact factor: 1.650

6.  Maltose-binding protein enhances secretion of recombinant human granzyme B accompanied by in vivo processing of a precursor MBP fusion protein.

Authors:  Benjamin Dälken; Robert A Jabulowsky; Pranav Oberoi; Itai Benhar; Winfried S Wels
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

7.  Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli.

Authors:  Hans Peter Sørensen; Kim Kusk Mortensen
Journal:  Microb Cell Fact       Date:  2005-01-04       Impact factor: 5.328

8.  A high-performance thioredoxin-based scaffold for peptide immunogen construction: proof-of-concept testing with a human papillomavirus epitope.

Authors:  Elena Canali; Angelo Bolchi; Gloria Spagnoli; Hanna Seitz; Ivonne Rubio; Thelma A Pertinhez; Martin Müller; Simone Ottonello
Journal:  Sci Rep       Date:  2014-04-22       Impact factor: 4.379

9.  Predictive approaches to guide the expression of recombinant vaccine targets in Escherichia coli: a case study presentation utilising Absynth Biologics Ltd. proprietary Clostridium difficile vaccine antigens.

Authors:  Hirra Hussain; Edward A McKenzie; Andrew M Robinson; Neill A Gingles; Fiona Marston; Jim Warwicker; Alan J Dickson
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-28       Impact factor: 4.813

10.  An oral recombinant Salmonella enterica serovar Typhimurium mutant elicits systemic antigen-specific CD8+ T cell cytokine responses in mice.

Authors:  Nyasha Chin'ombe; William R Bourn; Anna-Lise Williamson; Enid G Shephard
Journal:  Gut Pathog       Date:  2009-04-29       Impact factor: 4.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.